共 164 条
[1]
Mitsudomi T(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128
[2]
Morita S(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced Lancet Oncol. 13 239-246
[3]
Yatabe Y(2014) mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol. 15 213-222
[4]
Negoro S(2014)Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring Asian Pac J Cancer Prev 15 657-662
[5]
Okamoto I(2014) mutations (LUX-lung 6): an open-label, randomised phase 3 trial J Thorac Oncol 9 1340-1344
[6]
Tsurutani J(2015)Relationships between Medicine (Baltimore) 94 45-51
[7]
Rosell R(2017) mutation status of lung cancer and preoperative factors - are they predictive? Lung Cancer 109 453-458
[8]
Carcereny E(2014)Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients Ann Thorac Surg 98 52-61
[9]
Gervais R(2013)Correlations Between the J Thorac Oncol 8 216-222
[10]
Vergnenegre A(2016) Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma Interact Cardiovasc Thorac Surg 23 610-1828